PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

被引：4
|
作者：
Brown, Fiona [1 ]
Zhang, Yang [2 ]
Hinterschied, Claire [1 ]
Prouty, Alexander [1 ]
Sloan, Shelby [3 ]
Helmig-Mason, JoBeth [3 ]
Chung, Ji Hyun [1 ]
Vaddi, Kris [2 ]
Chen-Kiang, Selina [4 ]
Di Liberto, Maurizio [4 ]
Alinari, Lapo [1 ]
Scherle, Peggy [2 ]
Lapalombella, Rosa [3 ]
Paik, Jihye [5 ]
Baiocchi, Robert A. [6 ]
机构：
[1] Ohio State Univ, Div Hematol, Dept Internal Med, Coll Med, Columbus, OH USA
[2] Prelude Therapeut, Wilmington, DE USA
[3] Ohio State Univ, Div Hematol, Dept Internal Med, Columbus, OH USA
[4] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA
[5] Cornell Univ, Paik Lab, New York, NY 10021 USA
[6] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-130797
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
302
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
    Algarin, Esperanza M.
    Diaz-Tejedor, Andrea
    Mogollon, Pedro
    Hernandez-Garcia, Susana
    Corchete, Luis A.
    San-Segundo, Laura
    Martin-Sanchez, Montserrat
    Gonzalez-Mendez, Lorena
    Schoumacher, Marie
    Banquet, Seprimebastien
    Kraus-Berthier, Laurence
    Kloos, Ioana
    Derreal, Alix
    Halilovic, Ensar
    Maacke, Heiko
    Gutierrez, Norma C.
    Mateos, Maria-Victoria
    Paino, Teresa
    Garayoa, Mercedes
    Ocio, Enrique M.
    HAEMATOLOGICA, 2020, 105 (03)
  • [32] Upregulated JAK/STAT Signaling Represents a Major Mode of Resistance to HDAC Inhibition In Lymphoma and Provides a Rationale for Novel Combination Therapy
    Smith, Jason
    Walsh, Katherine J.
    Jacobs, Cassandra L.
    Liu, Qingquan
    Fan, Siyao
    Patel, Amee
    Dave, Sandeep
    BLOOD, 2010, 116 (21) : 195 - 195
  • [33] Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma
    Thieme, Elana
    Liu, Tingting
    Bruss, Nur
    Roleder, Carly
    Lam, Vi
    Wang, Xiaoguang
    Nechiporuk, Tamilla
    Shouse, Geoffrey
    Danilova, Olga, V
    Bottomly, Daniel
    McWeeney, Shannon K.
    Tyner, Jeffrey W.
    Kurtz, Stephen E.
    Danilov, Alexey, V
    CELL DEATH & DISEASE, 2022, 13 (03)
  • [34] Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma
    Elana Thieme
    Tingting Liu
    Nur Bruss
    Carly Roleder
    Vi Lam
    Xiaoguang Wang
    Tamilla Nechiporuk
    Geoffrey Shouse
    Olga V. Danilova
    Daniel Bottomly
    Shannon K. McWeeney
    Jeffrey W. Tyner
    Stephen E. Kurtz
    Alexey V. Danilov
    Cell Death & Disease, 13
  • [35] An Epigenetic Screen Identifies PRMT5 As a Target for Inhibition of FLT3-ITD AML Cell Growth in Combination with Tyrosine Kinase Inhibitors
    Dhir, Aditi
    Paterson, Andrew J.
    Qiu, Shaowei
    Mullen, Amanda K.
    Anderson, Nick R.
    Bhatia, Ravi
    BLOOD, 2019, 134
  • [36] Inhibition of growth of human breast cancer cell lines with the combination of an mTOR inhibitor and a Bcl-2 inhibitor
    Wilson, Matthew
    Witters, Lois
    Lane, Heidi
    Lipton, Allan
    CANCER RESEARCH, 2006, 66 (08)
  • [37] Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma
    Froehlich, Tabea C.
    Mueller-Decker, Karin
    Braun, Jana D.
    Albrecht, Thomas
    Schroeder, Anne
    Guelow, Karsten
    Goerdt, Sergij
    Krammer, Peter H.
    Nicolay, Jan P.
    BLOOD, 2019, 134 (05) : 445 - 455
  • [38] Overcoming cell death resistance in cutaneous T cell lymphoma (CTCL) by combined Bcl-2 and NFκB inhibition
    Schloer, Tabea
    Mueller-Decker, Karin
    Schroeder, Anne
    Guelow, Karsten
    Goerdt, Sergij
    Krammer, Peter
    Nicolay, Jan P.
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : S29 - S29
  • [39] Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax
    Satta, Toshihisa
    Li, Lin
    Chalasani, Sri Lakshmi
    Hu, Xiaoyan
    Nkwocha, Jewel
    Sharma, Kanika
    Kmieciak, Maciej
    Rahmani, Mohamed
    Zhou, Liang
    Grant, Steven
    CLINICAL CANCER RESEARCH, 2023, 29 (07) : 1332 - 1343
  • [40] Protein Arginine Methyltransferase 5 (PRMT5) Inhibition Induces Lymphoma Cell Death through Reactivation of the Retinoblastoma Tumor Suppressor Pathway and Polycomb Repressor Complex 2 (PRC2) Silencing
    Chung, Jihyun
    Karkhanis, Vrajesh
    Tae, Sookil
    Yan, Fengting
    Smith, Porsha
    Ayers, Leona W.
    Agostinelli, Claudio
    Pileri, Stefano
    Denis, Gerald V.
    Baiocchi, Robert A.
    Sif, Said
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (49) : 35534 - 35547
12345